



AVICANNA™

Q3 2023

An International Biopharmaceutical Strategy

For Naturally Derived and Evidenced Based Products

TSX: AVCN
OTCQX: AVCNF
FSE: ONN

avicanna.com

© 2023 Avicanna Inc.

Forward-Looking Statements

Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable securities laws (“forward-looking statements”). Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements and information about anticipated dates for revenue recognition; business strategy, product development, timing of product development, events and courses of action, anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical studies/trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates, and beliefs at the they are made. Forward-looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna may operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these forward-looking statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance, or achievements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially deferent from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely impact our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for our products; the demand and pricing of cannabis and cannabidiol (“CBD”); security threats, including a loss/ theft of proprietary technology; our relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely abet our business; our ability to manage working capital; our dependence on key personnel; the severity, duration and effects of the pandemic related to COVID19 on our business, and additional risk factors included elsewhere in Avicanna’s public disclosure record, including, without limitation, under the heading “Risk Factors” in its annual information form dated March 31, 2022 and final short form prospectus dated November 27, 2020, in each case filed with the Canadian securities regulators and available under Avicanna’s profile on SEDAR at www.sedar.com.

Although Avicanna has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Avicanna is an early-stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna’s expectations include, consumer sentiment towards Avicanna’s products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and CBD, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counterparties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, unexpected delays in the commercialization of products and the severity, duration and effects of COVID19. Forward-looking statements contained in this presentation are as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Financial Information and Management Estimates

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein.

Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of management. Management believes that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete.

Third Party Information

Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Where this presentation quotes any information or data from any third-party source, it should not be interpreted that Avicanna has adopted or endorsed such information or data as being accurate. Avicanna has not independently verified any of such information from third-party sources or any underlying assumptions. Accordingly, Avicanna makes no representation or warranty (express or implied) on the fairness, accuracy, completeness or correctness of any such third-party information.


Disclaimer

No securities commission or similar authority of Canada, the United States or any other jurisdiction has reviewed or in any way passed upon this presentation, and any representation to the contrary is an offence. Readers should not construe the contents of this presentation as investment, legal, tax, regulatory, financial or accounting advice and are urged to consult with their own advisers in relation to such matters.



0.1 Timeline

Avicanna is a commercial and scale-up stage biopharmaceutical company established in R&D, and commercialization of evidence-based cannabinoid products for the international consumer, medical and pharmaceutical market segments. Supported by its Canadian scientific platform, Avicanna has successfully commercialized its proprietary products into 19 international markets.



0.2 Corporate highlights

An international medical and biopharmaceutical strategy

Scientific platform

- Established R&D and clinical platform
- Partnerships with leading academic and clinical institutions
- JLABS @Johnson and Johnson incubated – at MaRS
- Pharmaceutical pipeline

Commercial platform

- 5 active business pillars
- Addressing a global market opportunity – 20+ countries**
- MyMedi.ca – medical cannabis platform and pharmacy
- 30+ commercialized proprietary SKUs

** International footprint or commercial transactions in 20 countries




0.3 Avicanna's Five Business Pillars

Intellectual Property and Brands Owned by Avicanna



Medical Cannabis and
Wellness Products
Commercial




Pharmaceutical Pipeline
**In Development and
Registration Stages**



Cosmetics and
Skincare
Commercial



Active
Pharmaceutical
Ingredients
Commercial



Medical Cannabis
Pharmacy Platform
Commercial




1. Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

1.1 Established Scientific Platform




30+
*Proprietary
Commercial Products*



10+
Scientists



R&D
through several Health
Canada issued Cannabis
Research Licenses



7
Pending Patents



11
*Canadian Government
Research Grants
Awarded Since 2020*



*Commercial Stage
Advanced Drug Delivery
Systems Products*



1.2 World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017









2. Commercial Products & Pipeline

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products






2.1 RHO Phyto

Advanced Drug Delivery System Formulations
(CBD, THC, CBG) - for International Medical
and Wellness Market Segments

2.1.1 RHO Phyto and Medical Cannabis



- Successful proof of concept with market acceptance and medical community adoption in Canada
- 20+ formulations of (CBD, THC, CBG) products: Offered in a range of non-inhalation advanced drug delivery systems



2.1.2 Canadian Commercialization Infrastructure

118 Commercial Listings Across Medical and Retail Channels

Canadian Commercialization Infrastructure

National Medical Channels	Provincial Retail Channels
<div>      </div>	<div>     </div>



26

Proprietary Commercial SKUs
Across 4 Brands

7

National Medical Cannabis
Portals Offering Avicanna
Products Including MyMedi.ca

66

Commercial Listings Across
Medical Channels, Including 25
on MyMedi.ca

118

Total Commercial Listings
in Canada

As of End of Q2 2023



2.1.3 Successful Proof of Concept and Partnership with Medical Cannabis by Shoppers




Avicanna X Medical Cannabis by Shoppers Partnership, since 2019

- 23 commercial SKUs across 4 brands, strategic commercial and clinical partnership
- Successful segmentation medical patients and aging population

Nationwide Medical Cannabis Portal

- Led by Canada’s leading pharmacy retailer with more than 30,000+ registered cannabis patients

Graphs Showing the Results of RHO Phyto Branded Products on the MCbS Platform



79%

Patients aged 40+



55%

Female patients



11%

Total sales on Medical Cannabis by Shoppers portal




2.2.1 Introducing MyMedi.ca

Established Through Acquisition from Medical Cannabis by Shoppers



- Transition From Medical Cannabis by Shopper's Drug Mart Platform
- **Evidence-Driven** Medical Cannabis Marketplace and Online Pharmacy
- **Pharmacist-Led** and **Bilingual Patient** Support Programs and Customer Service
- Providing **Compassionate Pricing, Insurance Coverage** and **Adjudication** Through Private and Public Payors
- Offering **Medical Cannabis Education and Harm Reduction** to Patients
- Training and Education to the Medical Community
- Enhancing **Medical Cannabis Care** Through Research and Clinical Collaborations



HEALTHCARE PROVIDERS

1. Training on Dosing and Titration
2. Product Recommendation Guidelines
3. Educational Modules and Courses

HARM REDUCTION EDUCATION

1. Highlighting the Risks of Inhalation Products
2. Considerations To Mitigate the Risk of Adverse Events



2.2.2 MyMedi.ca Portfolio and Brands




200+ SKUs from 12 Licensed Producers



2.2.3 MyMedi.ca Highlights



- 19,428 Active Patients
- Those Between 40-69 Years of Age Make Up 60% of the Total Patient Group
- Although Insurance Coverage Only Makes Up 10.5% of the Patient Pool, These Patients Make Up for Nearly 65% of the Total Sales
- Weekly We See Between 400-500 New Medical Documents Submitted to the Platform
- Currently There Are Over 1,500 Actively Prescribing HCPs and Over 57 Clinic Partners



2.2.4 Medical Cannabis Education and Training



A federally-registered Canadian non-profit organization of basic and clinical researchers, health care professionals and educators that promote research and evidence-based education concerning the endocannabinoid system, the therapeutic applications of cannabinoids, the potential harms associated with cannabis use and the health and societal impacts of non-medical cannabis use.



A resource for health care professionals that are interested in learning more about the use and prescription of medical cannabis.



2.3.1 Pharmaceutical Pipeline and Drug Candidates

Designed to Address 5 Major Clinical Areas



Sleep



Eczema/
Epidermolysis
Bullosa



Pain
Management



Anxiety &
Depression



Epilepsy

- Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage
- Leveraging the company's scientific platform and vertical integration to deliver proprietary and accessible finished products





2.3.2 Trunerox™ 10% CBD (100 mg/ml Cannabidiol)

Pharmaceutical Drug Preparation Pending Market Authorization



- Pharmaceutical preparation under GMP standards with proprietary formulation with enhanced absorption
- Expected marketing authorization during late 2023/ early 2024 several South American markets
- Accessible pricing pharmaceutical preparation utilizing the company's vertical integration



2.4 Pura H&W: Clinically Backed CBD Dermocosmetic Products

Functional Skin Care Products Addressing Global Emerging CBD Consumer Product Segment

- **Proprietary and patent-pending line** of 13 premium topical products
- **Clinically backed** first line of CBD topical products supported by clinical results (clinicaltrials.gov)
- **Commercial internationally** across medical, adult use and consumer channels
- Current CBD over the counter **market size of \$7.3 bilion***
- CBD cosmetics are **legal in 50+ countries** and liberalizing internationally**



*Prohibition Partners

**<https://www.grandviewresearch.com/industry-analysis/cbd-skin-care-market>

2.5 Aureus Santa Marta: Cannabinoids and Standardized Genetics

Avicanna’s Supply Chain Business Unit and Vertical Integration

Raw Material Business Unit Branded as Aureus Santa Marta



- Avicanna’s **low cost and consistent** supply of cannabinoids for its finished products through **in-house cultivation and extraction**
- Providing the pharmaceutical partners with active pharmaceutical ingredients (API) with completed exports into **16 international markets**



Established, Sustainable and Economical Cultivation and Extraction Infrastructure



- Majority owned subsidiary in Santa Marta Colombia with **300,000 square feet and 26,000 kg of annual capacity**
- **USDA National Organic Program certified** and GACP certification
- 30+ completed harvest validating **below 10 cents per gram** cost
- Cultivating commercial crops of **CBD, CBG, THC and feminized seeds** since 2020





2.6 Avicanna Around the World

Completed Sales and Exports into 19 Countries

Product Line & Brand	Canada - Medical	Canada - Adult Use	USA	Colombia	UK	Ecuador
RHO Phyto / Medical/Wellness	✓	✓			2023	
Aureus API			✓	✓	✓	2023


Product Line & Brand	Brazil	Chile	Peru	Portugal	Germany	Barbados
RHO Phyto / Medical/Wellness						✓
Aureus API	✓	✓	✓	✓	✓	



3. Financial & Capital Overview

Highlights

- Common shares: 87M*
- Tightly held by insiders and strategic investors
- 200% Revenue growth between Q1-2023 to Q2 2023



*As of close of market September 5th 2023



TSX: AVCN

R&D and Pharmaceutical issuer on the TSX
senior exchange since IPO in 2019



OTCQX:
AVCNF



FSE:
ONN



3.1 Management and Board of Directors

Senior Management Team

Aras Azadian
Founder and CEO

Phillip Cardella
Chief Financial Officer

Stephen Kim
Chief Legal Officer & General Counsel

Ivana Marić
Executive Vice President, Marketing

Dr. Frantz Le Devedec, PhD
Executive Vice President, Research &
Product Development

Dr. Karolina Urban, PhD
Executive Vice President, Medical &
Scientific Affairs

Board of Directors

Aras Azadian
Founder and CEO

Eileen McCormack
Independant Director

John McVicar
Independant Director

Giancarlo Davila Char
Director



3.2 Corporate Highlights

De-risked investment - commercial stage, with key regulatory approvals and milestones achieved, with several product lines

Diversified - scalable and high margin revenue streams

Experienced management - proven track record since 2016

Intellectual property powerhouse - industry-leading scientific platform


Disruptive - pharmaceutical development approach to cannabinoid-based products

World-class partnerships - clinical and commercial relationships in Canada and LATAM

Vertical integration - low-cost and sustainable supply chain



AVICANNA™



MyMedi.ca
MEDICAL CANNABIS CARE



THANK YOU



AVICANNA™

